OculoMotor Technologies
Developing VR platform technologies to treat, diagnose, and enhance visual function to help kids of all ages improve their vision
- Stage Full Product Ready
- Industry Medical Devices and Equipment
- Location Newark, NJ, USA
- Currency USD
- Founded June 2018
- Employees 9
- Incorporation Type C-corp
- Website oculomotortechnologies.com
Company Summary
OculoMotor Technologies is developing platform technologies to quantify and amplify the visual system. With indications for symptomatic people suffering from a variety of visual disorders, healthy people seeking to improve their vision, and even concussed athletes trying to recover, OMTs’ technology is poised to take advantage of recent technological development in virtual reality, and significant market appetite in the realm of optometry.
Team
-
John Vito serves as CEO and Primary Investigator for OMT's SBIR grants. He has 7 years of experience in project management, and five years of experience in development of virtual reality technologies. He completed his B.S. and M.S. in biomedical engineering, and wrote his thesis on technology that laid the groundwork for OMT.
-
Chang Yaramothu, PhDChief Technology Officer
Dr. Yaramothu has 10 years of engineering experience with an expertise in eye movements. He led a longitudinal study on concussion using eye movements and engineering for his doctoral dissertation.
-
Tara Alvarez, PhDChief Science Officer
Dr. Alvarez has over 25 years of experience designing novel instruments to study neural control, oculomotor learning, and adaptation of eye movements integrated with brain imaging funded through two NSF MRI grants. Her NSF CAREER grant collected the pilot data that led an active 5 year NIH R01 that is statistically powered to understand how vision therapy changes the brain and corresponding behavior leading to a reduction in vision symptoms.
-
Mitchell Scheiman, OD PhDChief Medical Officer
Dr. Scheiman has 42 years of experiences as an optometrist. He has expertise in designing and studying vision therapy and has served as study chair for several randomized clinical trials including the Convergence Insufficiency Treatment Trial (CITT) and the CITT- Attention and Reading Trial. He is also leading a team of clinicians to study the effectiveness of conventional office-based vision therapy for patients with concussion-related CI.
Advisors
-
Matthew TuckerUnconfirmed
-
Hans HartmannUnconfirmed
Previous Investors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.